Survival of diffuse large cell lymphoma. A multivariate analysis including dose intensity variables

No abstract is available for this paper.

• Publication year

  1990

• Venue

  Cancer

• Publication date

  1990-09-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/1097-0142(19900915)66:6<1124::AID-CNCR2820660608>3.0.CO;2-TPMID 2205353
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Treatment of non‐Hodgkin's lymphoma

  1991cited by this paper
• The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma.

  1988cited by this paper
• Dose-intensity analysis for CHOP chemotherapy in diffuse aggressive large cell lymphoma.

  1988cited by this paper
• Interpretation of clinical trials in diffuse large-cell lymphoma.

  1988cited by this paper
• Average relative dose intensity and the impact on design of clinical trials.

  1987cited by this paper
• Impact of dose-intense chemotherapy on the development of permanent drug resistance.

  1987cited by this paper
• Impact of dose-intense chemotherapy on the development of permanent drug resistance.

  1987cited by this paper
• The chemotherapy of lymphomas: looking back, moving forward--the Richard and Hinda Rosenthal Foundation award lecture.

  1987cited by this paper
• Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology Group experience.

  1986cited by this paper
• Twenty years of MOPP therapy for Hodgkin's disease.

  1986cited by this paper
• A 10-year update of CHOP-Bleo in the treatment of diffuse large-cell lymphoma.

  1986cited by this paper
• High-dose adriamycin combination chemotherapy for intermediate and high-grade non-Hodgkin's lymphomas.

  1985cited by this paper
• The importance of dose intensity in chemotherapy of metastatic breast cancer.

  1984cited by this paper
• A dose and time response analysis of the treatment of Hodgkin's disease with MOPP chemotherapy.

  1983cited by this paper
• Measurement of drug dosage intensity in MVPP therapy in Hodgkin's disease.

  1980cited by this paper
• Dose: a critical factor in cancer chemotherapy.

  1980cited by this paper
• A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate.

  1979cited by this paper
• A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate.

  1979cited by this paper
• HOW STRONG IS THE CASE FOR INTENSIVE CANCER CHEMOTHERAPY

  1976cited by this paper
• How strong is the case for intensive cancer chemotherapy?

  1976cited by this paper
• Hydroxyldaunomycin (adriamycin) combination chemotherapy in malignant lymphoma

  1976cited by this paper
• Report of the Committee on Hodgkin's Disease Staging Classification.

  1971cited by this paper
• Evaluation of survival data and two new rank order statistics arising in its consideration.

  1966cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958cited by this paper
• Atlas of Tumor Pathology

  1954cited by this paper
• National

  1896cited by this paper
• Regression Models and Life-Tables

  year unknowncited by this paper

• Vincristine Induced Adverse Effects in Lymphoma Bearing Dogs With Asymptomatic Neutropenia at the Time of Drug Administration.

  2024cites this paper
• Efficacy and safety of dexamethasone sparing for the prevention of nausea and vomiting associated with moderately emetogenic chemotherapy: a systematic review and meta-analysis of Clinical Practice Guidelines for Antiemesis 2023 from Japan Society of Clinical Oncology

  2024cites this paper
• Efficacy and safety of multi-day antiemetic treatment for patients undergoing multi-day chemotherapy: a systematic review of Clinical Practice Guidelines for Antiemesis 2023 from Japan Society of Clinical Oncology

  2024cites this paper
• Calculation of dose intensity & comparison of published methods using a cohort of canine T-cell lymphoma patients undergoing CHOP-based chemotherapy.

  2023cites this paper
• Comparison of Tolerability Between 2-Weekly and 3-Weekly Docetaxel Regimen in Castration-resistant Prostate Cancer

  2020cites this paper
• The incidence and timing of leukocyte overshoot after pegfilgrastim administration

  2019cites this paper
• The average relative dose intensity of R‐CHOP is an independent factor determining favorable overall survival in diffuse large B‐cell lymphoma patients

  2019cites this paper
• Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study*

  2019cites this paper
• Frequency and impact of grade three or four toxicities of novel agents on outcomes of older patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma (alliance A151611).

  2018cites this paper
• Retrospective analysis of the impact of anthracycline dose reduction and chemotherapy delays on the outcomes of early breast cancer molecular subtypes

  2018cites this paper
• Impact of Provider Volume on Outcomes of Patients With Hodgkin Lymphoma

  2018cites this paper
• Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study.

  2018cites this paper
• Febrile neutropenia in patient with head and neck cancer treated with docetaxel, cisplatin and 5-fluorouracil (TPF protocol) - A comparison before and after the introduction of pegfilgrastim

  2017cites this paper
• Initial Experience with Nab-Paclitaxel for Patients with Advanced Gastric Cancer: Safety and Efficacy.

  2017cites this paper
• The care center influences the management of lymphoma patients in a universal health care system: an observational cohort study

  2016cites this paper
• Control of nausea with palonosetron versus granisetron, both combined with dexamethasone, in patients receiving cisplatin- or anthracycline plus cyclophosphamide-based regimens

  2016cites this paper
• The effect of chemotherapy-induced anemia on dose reduction and dose delay

  2016cites this paper
• Evaluation of the impact of treatment delays and dose reductions in human ovarian cancer orthotopic mouse models

  2016cites this paper
• Prevention of neutropenia during chemotherapy by prolonged myelostimulatory preparations

  2015cites this paper
• Comparison between 5-day aprepitant and single-dose fosaprepitant meglumine for preventing nausea and vomiting induced by cisplatin-based chemotherapy

  2015cites this paper
• Attitudes and practice patterns for maintaining relative dose intensity of chemotherapy in outpatient clinics: results of a Japanese web-based survey

  2015cites this paper
• Adjuvant chemotherapy for stage III colon cancer: relative dose intensity and survival among veterans

  2015cites this paper
• Influence of dose reduction of vincristine in R-CHOP on outcomes of diffuse large B cell lymphoma

  2015cites this paper
• A longitudinal study of non-medical determinants of adherence to R-CHOP therapy for diffuse large B-cell lymphoma: implication for survival

  2015influential citation
• Preclinical and Clinical Development of Angiotensin Peptides (Mas/Ang(1-7)/ACE-2): Future Clinical Application

  2015cites this paper
• Incidence, treatment, and consequences of chemotherapy-induced febrile neutropenia in the inpatient and outpatient settings

  2014cites this paper
• Phase II trial of carboplatin/docetaxel in patients with resected NSCLC

  2014cites this paper
• Modelling chemotherapy effects on granulopoiesis

  2014cites this paper
• A phase III randomized trial of high‐dose CEOP + filgrastim versus standard‐dose CEOP in patients with non‐Hodgkin lymphoma: 10‐year follow‐up data: Australasian Leukaemia and Lymphoma Group (ALLG) NHL07 trial

  2014cites this paper
• Suboptimal dosing of rituximab in male and female patients with DLBCL.

  2014cites this paper
• Clinical practice in febrile neutropenia risk assessment and granulocyte colony-stimulating factor primary prophylaxis of febrile neutropenia in Poland

  2014cites this paper
• The Prophylactic Use of Filgrastim in Patients with Hematological Malignancies

  2013cites this paper
• Efficacy and tolerability of reduced-dose 21-day cycle rituximab and cyclophosphamide, doxorubicin, vincristine and prednisolone therapy for elderly patients with diffuse large B-cell lymphoma

  2013cites this paper
• Diffuse large B-cell lymphoma in the elderly: leaving our old way(s) behind?

  2013cites this paper
• Contribution of the Local RAS to Hematopoietic Function: A Novel Therapeutic Target

  2013cites this paper
• Pharmacokinetics and pharmacodynamics of vincristine sulfate liposome injection (VSLI) in adults with acute lymphoblastic leukemia

  2013cites this paper
• シスプラチン投与口腔癌患者に対する新規NK1受容体拮抗薬ホスアプレピタント（プロイメンド®）の有効性

  2013cites this paper
• Comparison of Cancer Care and Outcomes between a Public Safety-Net Hospital and a Private Cancer Center

  2013cites this paper
• Use of Filgrastim and Pegfilgrastim to Support Delivery of Chemotherapy

  2012influential citation
• Steroid Withdrawal Syndrome after Normal Dose Chemotherapy in Non-Hodgkin's Lymphoma -A Study of the Frequency of Symptoms and the Efficacy of Steroid Tapering-

  2012cites this paper
• High-dose chemotherapy with hematopoietic stem cell transplantation for the treatment of primary central nervous system lymphoma

  2011cites this paper
• Importance of relative dose intensity in chemotherapy for diffuse large B-cell lymphoma.

  2011cites this paper
• Costs and outcomes associated with hospitalized cancer patients with neutropenic complications: A retrospective study.

  2011cites this paper
• Importance of maintaining the relative dose intensity of CHOP-like regimens combined with rituximab in patients with diffuse large B-cell lymphoma

  2010cites this paper
• Utility of routine nurse assessment of the risk of chemotherapy-induced febrile neutropenia.

  2010cites this paper
• Treatment of patients with diffuse large B-cell lymphoma

  2010cites this paper
• Impact of relative dose intensity (RDI) in CHOP combined with rituximab (R-CHOP) on survival in diffuse large B-cell lymphoma

  2009cites this paper
• Recent developments in the treatment of aggressive non-Hodgkin lymphoma.

  2009cites this paper
• Impact of chemotherapy dose intensity on cancer patient outcomes.

  2009cites this paper
• Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP

  2008cites this paper
• Clinical practice guidelines for the use of colony-stimulating factors in cancer treatment: Implications for oncology nurses.

  2008cites this paper
• Pegfilgrastim; a neutrophil mediated granulocyte colony stimulating factor–expanding uses in cancer chemotherapy

  2008cites this paper
• Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice.

  2008cites this paper
• Effectiveness of cytopenia prophylaxis for different fi lgrastim and peg fi lgrastim schedules in a chemotherapy mouse model

  2008cites this paper
• randomized trial of PAdriaCEBO versus PMitCEBO patients older than 60 with high-grade lymphoma: results of a BNLI Mitoxantrone is superior to doxorubicin in a multiagent weekly regimen for

  2008cites this paper
• Effectiveness of cytopenia prophylaxis for different filgrastim and pegfilgrastim schedules in a chemotherapy mouse model

  2008cites this paper
• Management of Chemotherapy-Induced Neutropenia: Opportunities for Pharmacist Involvement

  2008cites this paper
• Neutropenic events in community practices reduced by first and subsequent cycle pegfilgrastim use.

  2007cites this paper
• Current Trends in Pharmacy Benefit Designs: A Threat to Disease Management in Chronic Complex Diseases

  2007cites this paper
• Canadian supportive care recommendations for the management of neutropenia in patients with cancer

  2007cites this paper
• Maintaining the dose intensity of ICE chemotherapy with a thrombopoietic agent, PEG-rHuMGDF, may confer a survival advantage in relapsed and refractory aggressive non-Hodgkin lymphoma.

  2007cites this paper
• Impact of chemotherapeutic dose intensity and hematologic toxicity on first remission duration in dogs with lymphoma treated with a chemoradiotherapy protocol.

  2007cites this paper
• Malignant lymphomas in the elderly: a single institute experience highlights future directions.

  2007cites this paper
• Low incidence of neutropenic events in patients with lymphoma receiving first-cycle pegfilgrastim with chemotherapy: results from a prospective community-based study.

  2007cites this paper
• Chemotherapy dose intensity and quality cancer care.

  2006cites this paper
• The impact of first and subsequent cycle pegfilgrastim on neutropenic events in patients receiving myelosuppressive chemotherapy in community practice: Interim results of the prospective FIRST study

  2006cites this paper
• Development and implementation of a risk assessment tool for chemotherapy-induced neutropenia.

  2006cites this paper
• Dose-dense Chemotherapy for Aggressive Non-Hodgkin Lymphoma

  2006cites this paper
• Prechemotherapy assessment of neutropenic risk.

  2006cites this paper
• Achieving Full-Dose, On-Schedule Administration of ACE Chemotherapy Every 14 Days for the Treatment of Patients with Extensive Small-Cell Lung Cancer

  2006cites this paper
• Holistic Nursing Practice: CALL FOR PAPERS

  2006cites this paper
• Pegfilgrastim: a granulocyte colony-stimulating factor with sustained duration of action

  2005cites this paper
• A combined analysis of average relative dose intensity in the chemotherapy of solid tumors with pegfilgrastim or filgrastim support.

  2005cites this paper
• Chemotherapy dose intensity in non-Hodgkin's lymphoma: is dose intensity an emerging paradigm for better outcomes?

  2005cites this paper
• Neutropenia management with granulocyte colony-stimulating factors: from guidelines to nursing practice protocols.

  2005cites this paper
• Increasing chemotherapy dose density and intensity: phase I trials in non-small cell lung cancer and non-Hodgkin's lymphoma.

  2005cites this paper
• Protocols for Managing Chemotherapy‐induced Neutropenia in Clinical Oncology Practices

  2005cites this paper
• Guidelines of the National Comprehensive Cancer Network on the use of myeloid growth factors with cancer chemotherapy: a review of the evidence.

  2005cites this paper
• Current and future use of hematopoietic growth factors in cancer medicine

  2004cites this paper
• Chemotherapy‐induced neutropenia

  2004cites this paper
• The impact of medical visits for chemotherapy-induced anemia and neutropenia on the patient and caregiver: a national survey

  2004cites this paper
• Increased risk of myelotoxicity in elderly patients with non‐Hodgkin lymphoma

  2004cites this paper
• BEYOND THE GUIDELINES : ADVANCES IN SUPPORTIVE CARE FOR PATIENTS WITH CANCER —

  2004cites this paper
• Chemotherapy Dose Density in Early‐Stage Breast Cancer and Non‐Hodgkin's Lymphoma

  2004cites this paper
• New treatment strategies for aggressive lymphoma.

  2004cites this paper
• Poor prognosis in elderly patients with cancer: the role of bias and undertreatment.

  2003cites this paper
• Impact of Dose-Intense and Dose-Dense Approaches on Outcome in Aggressive Non-Hodgkin's Lymphoma

  2003cites this paper
• Balancing the benefits and costs of colony-stimulating factors: a current perspective.

  2003cites this paper
• Risk Assessment in Oncology Clinical Practice

  2003cites this paper
• Myelotoxicity and dose intensity of chemotherapy: reporting practices from randomized clinical trials.

  2003cites this paper
• New paradigms for treating elderly patients with cancer: the comprehensive geriatric assessment and guidelines for supportive care.

  2003cites this paper
• Fourteen-day CHOP supported with granulocyte colony-stimulating factor in patients with aggressive non-Hodgkin's lymphoma: results of a phase II study.

  2003cites this paper
• Current management of chemotherapy-induced neutropenia: the role of colony-stimulating factors.

  2003cites this paper
• Chemotherapy in the elderly: supportive measures for chemotherapy-induced myelotoxicity.

  2003cites this paper
• Randomized phase II study of biweekly CHOP and dose-escalated CHOP with prophylactic use of lenograstim (glycosylated G-CSF) in aggressive non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9505.

  2002cites this paper
• Dose intensity and clinical response in head and neck carcinoma treated with cisplatin + 5-fluorouracil

  2002cites this paper
• The geriatric cancer patient: equal benefit from equal treatment.

  2001cites this paper
• Mitoxantrone is superior to doxorubicin in a multiagent weekly regimen for patients older than 60 with high-grade lymphoma: results of a BNLI randomized trial of PAdriaCEBO versus PMitCEBO.

  2001cites this paper
• Dose-escalation study of CHOP with or without prophylactic G-CSF in aggressive non-Hodgkin's lymphoma.

  2000cites this paper
• [Prognostic factors in non-Hodgkin's lymphoma of Waldeyer's ring and the lymph nodes of the neck].

  2000cites this paper